Jackie Collins


Nivolumab/Cabozantinib combo continues to show HRQOL benefit in renal cell carcinoma

February 25, 2022

Long-term follow-up from the CheckMate 9ER trial continued to show that first-line treatment with nivolumab plus cabozantinib was associated with a health-related quality-of-life benefit over treatment with sunitinib in patients with advanced renal cell carcinoma .